Results 11 to 20 of about 1,131 (155)

Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Solid Tumors. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Selpercatinib is a first‐in‐class, highly selective, RET kinase inhibitor with CNS activity, approved for the treatment of RET‐altered lung, thyroid, and other cancers. We report pharmacokinetic analyses to identify factors affecting selpercatinib steady‐state exposure and support posology in pediatric patients.
Liu D, van der Walt JS.
europepmc   +2 more sources

A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene-Positive Non-Small Cell Lung Cancer. [PDF]

Respirol Case Rep
We report a case of selpercatinib‐induced syndrome of inappropriate secretion of antidiuretic hormone (SIADH) that improved after drug withdrawal and was safely resumed at a reduced dose. ABSTRACT An 80‐year‐old woman with a lung nodule in the right lower lobe and pleural thickening was diagnosed with lung adenocarcinoma by a surgical lung biopsy.
Tanaka Y, Ikegami N, Miyamoto K, Shingu Y, Okagaki N, Sakamoto H, Nakanishi T, Nakamura S, Matsumura K, Ueyama M, Kaji Y, Hashimoto S, Tanaka E, Taguchi Y, Ohsumi Y, Nakagawa T, Matsunaga S, Hajiro T.   +17 more
europepmc   +2 more sources

Treatment of non-small cell lung cancer with RET rearrangements. [PDF]

Cancer
Abstract Aberrant activation of the RET oncogene by mutations or gene fusions drives various malignancies, including 1%–2% of all non–small cell lung cancers (NSCLCs) that harbor RET gene fusions. Initial attempts to target RET fusion–positive NSCLC with poorly selective multikinase RET inhibitors were associated with significant toxicities and limited
Hoe HJ, Solomon BJ.
europepmc   +2 more sources

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth, Bruce Robinson, Valentina Boni, Daniel S.W. Tan, Caroline McCoach, Erminia Massarelli, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Vivek Subbiah   +10 more
wiley   +1 more source

Neoadjuvant Selpercatinib for Stage IIIA Primary Pulmonary Adenocarcinoma With RET Fusion: A Case Report. [PDF]

Respirol Case Rep
This case describes a 55‐year‐old female with stage IIIA RET fusion‐positive lung adenocarcinoma and thromboembolic contraindications who achieved significant tumour downstaging after neoadjuvant selpercatinib therapy, enabling successful curative resection.
Cui Z, Hu Y, Zhao J, Mu C, Li C.
europepmc   +2 more sources

First Report of <i>RET</i> Fusion-Positive Lung Adenocarcinoma With Miliary Intrapulmonary Metastases Responsive to Selpercatinib: A Case Report. [PDF]

Clin Case Rep
ABSTRACT Lung cancer presenting with miliary lung metastases on chest computed tomography is associated with poor prognosis. Recent studies indicate that non‐small cell lung cancer harboring driver gene mutations, including rearranged during transfection (RET) fusions, can manifest with miliary lung metastases.
Iwanaka S, Nishimura T, Fujimoto H, Morita D, Kuru H, Sakakura Y, D'Alessandro-Gabazza CN, Yasuma T, Gabazza EC, Naito M, Ibata H, Kobayashi T.   +11 more
europepmc   +2 more sources

Assessing tolerability of cancer therapeutics: A regulatory perspective from the FDA Oncology Center of Excellence. [PDF]

Cancer
Abstract Patient‐reported symptoms and functioning are valuable to understanding the tolerability of cancer treatments in clinical trials. Assessment of key side effects, physical and role functioning, and overall side effect bother in trials may be helpful for benefit–risk evaluation and useful to communicate in product labeling.
Bhatnagar V, Lee Johnson L, Fiero MH, Mulkey F, Kluetz P.   +4 more
europepmc   +2 more sources

O możliwościach czytania dzieła operowego

Przestrzenie Teorii, 2015
Elżbieta Nowicka’s book Zapisane w operze. Studia z historii i estetyki opery (Wydawnictwo Poznańskie 2012) [Written in opera. The studies from history and aesthetics of opera] is an attempt to read the ideas, myths and idioms of culture enshrined in ...
Anna Wypych-Gawrońska
doaj   +1 more source

Strategie polskich tłumaczy włoskich librett w XVIII wieku

Między Oryginałem a Przekładem, 2013
Strategies in Translating Italian Librettos in 18th Century Poland Polish dramatic writers of the 18th century very often referred to the European repertoire. The majority of Polish dramas in fact were translations or adaptations of foreign texts. Among
Jadwiga Miszalska
doaj   +1 more source

Written on Skin by George Benjamin: Aspects of the Plot and Libretto of the Opera Masterpiece of Our Days [PDF]

Художественная культура
The 20th century in the musical art was marked by relentless changes and experiments which we are still observing. Many things were questioned, including the possibility of the existence of such a traditional genre as opera in the current artistic ...
Saamishvili Natalia N.
doaj   +1 more source